- Home
- ARVN vs BALY Comparison
ARVN vs BALY Comparison
Compare ARVN & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- BALY
- Stock Information
- Founded
- ARVN 2015
- BALY 2004
- Country
- ARVN United States
- BALY United States
- Employees
- ARVN N/A
- BALY 10000
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- BALY Hotels/Resorts
- Sector
- ARVN Health Care
- BALY Consumer Discretionary
- Exchange
- ARVN Nasdaq
- BALY Nasdaq
- Market Cap
- ARVN 456.2M
- BALY 470.5M
- IPO Year
- ARVN 2018
- BALY N/A
- Fundamental
- Price
- ARVN $7.90
- BALY $9.88
- Analyst Decision
- ARVN Buy
- BALY Hold
- Analyst Count
- ARVN 22
- BALY 7
- Target Price
- ARVN $20.21
- BALY $18.00
- AVG Volume (30 Days)
- ARVN 1.8M
- BALY 363.4K
- Earning Date
- ARVN 10-29-2025
- BALY 02-19-2025
- Dividend Yield
- ARVN N/A
- BALY N/A
- EPS Growth
- ARVN N/A
- BALY N/A
- EPS
- ARVN N/A
- BALY N/A
- Revenue
- ARVN $372,800,000.00
- BALY $2,481,783,000.00
- Revenue This Year
- ARVN $4.87
- BALY $3.06
- Revenue Next Year
- ARVN N/A
- BALY N/A
- P/E Ratio
- ARVN N/A
- BALY N/A
- Revenue Growth
- ARVN 299.57
- BALY 2.80
- 52 Week Low
- ARVN $5.90
- BALY $9.74
- 52 Week High
- ARVN $29.61
- BALY $18.38
- Technical
- Relative Strength Index (RSI)
- ARVN 60.55
- BALY 52.20
- Support Level
- ARVN $7.62
- BALY $9.89
- Resistance Level
- ARVN $8.22
- BALY $10.25
- Average True Range (ATR)
- ARVN 0.31
- BALY 0.42
- MACD
- ARVN 0.10
- BALY 0.06
- Stochastic Oscillator
- ARVN 76.98
- BALY 73.84
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, and entertainment company with a portfolio of casinos and resorts and a growing omnichannel presence. It provides customers with physical and interactive entertainment and gaming experiences, including traditional casino offerings, iGaming, online bingo, sportsbook, and free-to-play (F2P) games. The company owns and operates, several casinos across the United States, one golf course in New York, one horse racetrack in Colorado, and Aspers Casino in the United Kingdom. Its Interactive International division, an interactive gaming operator concentrated in Europe, operates a lottery management and services business. The company's reportable segments are Casinos and Resorts, which derive key revenue, International Interactive and North America Interactive.